RxDoctor Payments Data

Timur Mitin

Radiation Oncology · Hillsboro, ORNPI 1679745822

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by AstraZeneca at 56.0% of the total. Among radiation oncology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,594in general payments, 2019–2025

Across 55 payments — averaging $1047.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$32K
  • Novocure Inc.$24K
  • Janssen Scientific Affairs, LLC$1K
  • Boston Scientific$70
$267,069in research payments, 2019–2025

Across 6 payments — averaging $44,512 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$129K
  • Novocure Inc.$89K
  • Janssen Research & Development, LLC$49K

What the payments were for

  • Consulting fees$15,66027%
  • Speaking & faculty fees$34,47560%
  • Travel & lodging$6,25911%
  • Food & beverage$1,2002%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca24$32,256
Novocure Inc.29$24,168
Janssen Scientific Affairs, LLC1$1,100
Boston Scientific1$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,594 in reported general payments places this provider in the 95th percentile of 93 radiation oncology providers in Oregon.

See all radiation oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$92,114
Medicare patients
213
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluconazole14$481
Lidocaine Hcl ViscousLidocaine Hcl19$284
Levothyroxine Sodium27$139

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Hillsboro

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →